Demographic and clinical characteristics
| Characteristic | |
|---|---|
| Values are per cent, n, or mean (SD) as indicated. | |
| *Range 5 to 15 mg leflunomide daily. | |
| †At least one active prescription at the point of sampling (low dose salicylates (<100 mg daily) not included). | |
| DMARD, disease modifying antirheumatic drug; NSAID, non-steroidal anti-inflammatory drug. | |
| Number of patients | 52 |
| Age (years) | 69 (12) |
| Female | 67% |
| Time since diagnosis of rheumatoid arthritis (years) | 11 (10) |
| Rheumatoid factor positive | 71% |
| Leflunomide prescribed as first DMARD | 21% |
| DMARDs before leflunomide (n) | 2.0 (1.7) |
| Range | 0 to 6 |
| >1 Year of leflunomide treatment | 90% |
| >2 Years of leflunomide treatment | 60% |
| Duration of leflunomide use (days) | 921 (299) |
| Range | 136 to 1327 |
| Prescribed daily leflunomide dose | |
| 10 mg | 25% |
| 20 mg | 65% |
| Other* | 10% |
| Concomitant corticosteroid use | 44% |
| Concomitant other DMARD use | 8% |
| Concomitant NSAID use† | 58% |